Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Manchestertimes
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved…
-
Noosa News10 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News15 hours agoLarge fleet of Robinson R22 helicopters sold as HM Air flies in another direction
-
General8 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News9 hours agoLyka Doggie Date Night at Moonlight Cinema